Abcam acquires California-based antibodies developer Calico Biolabs
Category: #health  By Nikita Chaurasia  Date: 2019-01-28
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Abcam acquires California-based antibodies developer Calico Biolabs

U.K. biotech firm Abcam has recently confirmed the acquisition of Calico Biolabs, a specialist in rabbit monoclonal antibodies based out of California. Calico is known to provide custom, high-quality recombinant rabbit monoclonal antibodies developed for and used by biopharmaceutical and diagnostic companies.

Apparently, the deal would help to extend the industry leading position of Abcam in rabbit monoclonal antibodies, bringing forth a portfolio of ready-made CAL antibodies™ for immunohistochemistry (IHC), besides Calico’s customer development services. Calico has partnered with several leaders in diagnostics and biopharmaceuticals for creating custom products to be used in companion diagnostics.

The ready-made recombinant CAL antibodies™ from Calico for critical immuno-oncology targets would be available at both commercial and research scale through Abcam’s global commercial network. The company did not disclose financial terms regarding the deal, though it is projected to have minimal impact on earnings and revenue for fiscal year 2019. Announcement of the deal had reportedly propelled Abcam’s share prices in the U.K.

Calico CEO Jacinto Villanueva was quoted saying that Abcam is leading supplier of high-quality validated antibodies, supported by an innovative approach towards production as well as commercialization. This transaction will allow Calico to comprehensively support cancer research and associated diagnostics development, which is being carried out by its industry partners, Villanueva mentioned.

John Baker, Abcam’s SVP of Product Portfolio and Innovation, said acquiring Calico Biolabs is representative of the company’s execution of its strategy for providing highest-quality products to its customers in the diagnostic, biopharmaceutical and research sectors. He confirmed that Abcam has expanded its offerings of rabbit monoclonal for IHC by incorporating Calico’s custom services and product portfolio.

Baker stated that Abcam will be able to develop more products for its most important targets and that too faster. Bringing the Calico team to the Abcam family will boost Abcam’s mission to offer highest quality recombinant antibodies for research to its customers.

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...